Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise...

por Cao, A-Yong, He, Min, Huang, Liang, Shao, Zhi-Ming, Di, Gen-Hong
Publicado 2013

Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer

por Huang, Liang, Liu, Qi, Lang, Guan-Tian, Cao, A-Yong, Shao, Zhi-Ming
Publicado 2020

A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes

por Huang, Liang, Lang, Guan-Tian, Liu, Qi, Shi, Jin-Xiu, Shao, Zhi-Ming, Cao, A-Yong
Publicado 2021

Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population

por Cao, A-Yong, Huang, Liang, Wu, Jiong, Lu, Jin-Song, Liu, Guang-Yu, Shen, Zhen-Zhou, Shao, Zhi-Ming, Di, Gen-Hong
Publicado 2012

Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk

por Lang, Guan-Tian, Shi, Jin-Xiu, Huang, Liang, Cao, A-Yong, Zhang, Chen-Hui, Song, Chuan-Gui, Zhuang, Zhi-Gang, Hu, Xin, Huang, Wei, Shao, Zhi-Ming
Publicado 2020

Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?

por Qu, Fei-Lin, Lin, Cai-Jin, Liu, Zhe-Bin, Cao, A.-Yong, Wu, Jiong, Liu, Guang-Yu, Yu, Ke-Da, Di, Gen-Hong, Li, Jun-Jie, Shao, Zhi-Ming
Publicado 2022

Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery

por Qu, Fei-Lin, Mao, Rui, Liu, Zhe-Bin, Lin, Cai-Jin, Cao, A-Yong, Wu, Jiong, Liu, Guang-Yu, Yu, Ke-Da, Di, Gen-Hong, Li, Jun-Jie, Shao, Zhi-Ming
Publicado 2021

A recessive variant of XRCC4 predisposes to non-BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization

por He, Min, Hu, Xin, Chen, Li, Cao, A-Yong, Yu, Ke-Da, Shi, Ting-Yan, Kuang, Xia-Ying, Shi, Wen-Biao, Ling, Hong, Li, Shan, Qiao, Feng, Yao, Ling, Wei, Qingyi, Di, Gen-Hong, Shao, Zhi-Ming
Publicado 2014

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

por Liu, Yin, Zhu, Xiu-Zhi, Xiao, Yi, Wu, Song-Yang, Zuo, Wen-Jia, Yu, Qiang, Cao, A-Yong, Li, Jun-Jie, Yu, Ke-Da, Liu, Guang-Yu, Wu, Jiong, Sun, Tao, Cui, Jiu-Wei, Lv, Zheng, Li, Hui-Ping, Zhu, Xiao-Yu, Jiang, Yi-Zhou, Wang, Zhong-Hua, Shao, Zhi-Ming
Publicado 2023

Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing

por Lang, Guan-Tian, Jiang, Yi-Zhou, Shi, Jin-Xiu, Yang, Fan, Li, Xiao-Guang, Pei, Yu-Chen, Zhang, Chen-Hui, Ma, Ding, Xiao, Yi, Hu, Peng-Chen, Wang, Hai, Yang, Yun-Song, Guo, Lin-Wei, Lu, Xun-Xi, Xue, Meng-Zhu, Wang, Peng, Cao, A-Yong, Ling, Hong, Wang, Zhong-Hua, Yu, Ke-Da, Di, Gen-Hong, Li, Da-Qiang, Wang, Yun-Jin, Yu, Ying, Shi, Le-Ming, Hu, Xin, Huang, Wei, Shao, Zhi-Ming
Publicado 2020

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

por Chen, Li, Jiang, Yi-Zhou, Wu, Song-Yang, Wu, Jiong, Di, Gen-Hong, Liu, Guang-Yu, Yu, Ke-Da, Fan, Lei, Li, Jun-Jie, Hou, Yi-Feng, Hu, Zhen, Chen, Can-Ming, Huang, Xiao-Yan, Cao, A-Yong, Hu, Xin, Zhao, Shen, Ma, Xiao-Yan, Xu, Ying, Sun, Xiang-Jie, Chai, Wen-Jun, Guo, Xiaomao, Chen, Xizi, Xu, Yanhui, Zhu, Xiao-Yu, Zou, Jian-Jun, Yang, Wen-Tao, Wang, Zhong-Hua, Shao, Zhi-Ming
Publicado 2022